Coronary hemodynamic effects of intravenous vasoactive intestinal peptide in humans.

Smitherman TC, Popma JJ, Said SI, Krejs GJ, Dehmer GJ

The American journal of physiology1 Oct 1989Cited by 18 (Europe PMC)

PMID2801984DOI10.1152/ajpheart.1989.257.4.h1254PepBankPUB-02801984

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In 11 men, intravenous VIP at the second infusion rate decreased coronary vascular resistance by 33%.
In plain wordsIn 11 men, VIP given into a vein lowered resistance in the heart's blood vessels, which widens them.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseCoronary vascular resistance during intravenous infusion
Study
n = 11
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous infusionAs given in this study (human).
Measurements
Coronary vascular resistance decrease
33%
second infusion
Source sentences
Summary
The decreases in coronary and systemic vascular resistances during the second infusion, 33 and 31%, respectively, were slightly but insignificantly greater than the 24% decrease in pulmonary vascular resistance.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the coronary hemodynamic effects of intravenously infused VIP in 11 men at two rates that modestly raised circulating VIP concentrations.
Report a problemFND-0280198401
02HumanNon-randomized trialEfficacy outcome
In 11 men, intravenous VIP at the second infusion rate decreased systemic vascular resistance by 31%.
In plain wordsIn 11 men, VIP given into a vein lowered resistance in the blood vessels of the body.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseSystemic vascular resistance during intravenous infusion
Study
n = 11
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous infusionAs given in this study (human).
Measurements
Systemic vascular resistance decrease
31%
second infusion
Source sentences
Summary
The decreases in coronary and systemic vascular resistances during the second infusion, 33 and 31%, respectively, were slightly but insignificantly greater than the 24% decrease in pulmonary vascular resistance.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the coronary hemodynamic effects of intravenously infused VIP in 11 men at two rates that modestly raised circulating VIP concentrations.
Report a problemFND-0280198402
03HumanNon-randomized trialEfficacy outcome
In 11 men, intravenous VIP at the second infusion rate decreased pulmonary vascular resistance by 24%.
In plain wordsIn 11 men, VIP given into a vein lowered resistance in the blood vessels of the lungs.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePulmonary vascular resistance during intravenous infusion
Study
n = 11
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous infusionAs given in this study (human).
Measurements
Pulmonary vascular resistance decrease
24%
second infusion
Source sentences
Summary
The decreases in coronary and systemic vascular resistances during the second infusion, 33 and 31%, respectively, were slightly but insignificantly greater than the 24% decrease in pulmonary vascular resistance.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the coronary hemodynamic effects of intravenously infused VIP in 11 men at two rates that modestly raised circulating VIP concentrations.
Report a problemFND-0280198403
04HumanNon-randomized trialEfficacy outcome
In 11 men, coronary sinus levels of 6-keto-prostaglandin F1 alpha were not elevated during intravenous VIP infusions.
In plain wordsIn 11 men, VIP given into a vein did not raise a blood marker of prostaglandin activity in the heart.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeCoronary sinus 6-keto-prostaglandin F1 alpha during infusion
Study
n = 11
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous infusionAs given in this study (human).
Source sentences
Summary
Coronary sinus levels of 6-keto-prostaglandin F1 alpha were not elevated during the infusions
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the coronary hemodynamic effects of intravenously infused VIP in 11 men at two rates that modestly raised circulating VIP concentrations.
Report a problemFND-0280198404
05HumanNon-randomized trialEfficacy outcome
In 11 men, cyclooxygenase inhibition did not significantly blunt coronary vasodilation produced by intravenous VIP.
In plain wordsIn 11 men, blocking cyclooxygenase did not clearly reduce the widening of heart vessels caused by VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeCoronary vasodilation after cyclooxygenase inhibition
Study
n = 11
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous infusionAs given in this study (human).
Source sentences
Summary
and cyclooxygenase inhibition did not significantly blunt coronary vasodilation.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the coronary hemodynamic effects of intravenously infused VIP in 11 men at two rates that modestly raised circulating VIP concentrations.
Report a problemFND-0280198405
06HumanNon-randomized trialEfficacy outcome
In 11 men, myocardial oxygen uptake rose significantly during both intravenous VIP infusions.
In plain wordsIn 11 men, VIP given into a vein raised the oxygen use of the heart muscle.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseMyocardial oxygen uptake during intravenous infusion
Study
n = 11
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous infusionAs given in this study (human).
Source sentences
Summary
However, myocardial oxygen uptake rose significantly during both infusions.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the coronary hemodynamic effects of intravenously infused VIP in 11 men at two rates that modestly raised circulating VIP concentrations.
Report a problemFND-0280198406
07HumanNon-randomized trialEfficacy outcome
In four men, intracoronary VIP produced a maximum decline in coronary vascular resistance of 46%.
In plain wordsIn four men, VIP given directly into a heart artery lowered resistance in the heart's blood vessels, at most by 46%.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseCoronary vascular resistance after intracoronary infusion
Study
n = 4
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intracoronaryAs given in this study (human).
Measurements
Maximum decline in coronary vascular resistance
46%
intracoronary VIP
Source sentences
Summary
To test for a direct coronary vasodilator effect, we infused VIP into the left coronary artery of four other men at four levels. The maximum decline in coronary vascular resistance was 46% and was not associated with an increase in myocardial oxygen uptake.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the coronary hemodynamic effects of intravenously infused VIP in 11 men at two rates that modestly raised circulating VIP concentrations.
Report a problemFND-0280198407
08HumanNon-randomized trialEfficacy outcome
In four men, the maximum decline in coronary vascular resistance with intracoronary VIP was not associated with an increase in myocardial oxygen uptake.
In plain wordsIn four men, VIP given directly into a heart artery widened the vessels without raising the oxygen use of the heart muscle.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeMyocardial oxygen uptake after intracoronary infusion
Study
n = 4
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intracoronaryAs given in this study (human).
Source sentences
Summary
To test for a direct coronary vasodilator effect, we infused VIP into the left coronary artery of four other men at four levels. The maximum decline in coronary vascular resistance was 46% and was not associated with an increase in myocardial oxygen uptake.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the coronary hemodynamic effects of intravenously infused VIP in 11 men at two rates that modestly raised circulating VIP concentrations.
Report a problemFND-0280198408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Coronary hemodynamic effects of intravenous vasoactive intestinal peptide in humans.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms